Glaxosmithkline Share News (GSK)

IN BRIEF: GSK reaches settlement over Zantac case in Illinois

GSK PLC - London based pharmaceuticals company - Reaches confidential settlement with Martin Gross resolving the case he filed in Illinois state court regarding Zantac. GSK does not admit any liability in this settlement. The case will now be dismissed as to GSK. Continues to vigorously defend itself and manage this litigation in the best interests of the company and shareholders.

European shares subdued ahead of economic data, French elections; H&M plunges

H&M tumbles after missing quarterly profit forecasts

*

London's FTSE 100 slips as investors eye US, UK economic data

FTSE 100 down 0.6%, FTSE 250 adds 0.2%

*

GSK shares slide after US health agency narrows scope of RSV shots

GSK shares fall as much as 7%

*

London close: Stocks mixed ahead of key UK, US data

(Sharecast News) - London stocks ended Thursday's trading session with a mixed performance as market participants awaited crucial US inflation data and UK GDP figures set to be released later in the week.

LONDON MARKET MIDDAY: Tepid trade as eyes on elections, US inflation

(Alliance News) - Stock prices in Europe struggled to make headway heading into Thursday afternoon, with sentiment cautious on the penultimate trading day of the quarter.

GSK shares drop as US narrows recommendations for RSV vaccines

(Sharecast News) - Shares in biopharma giant GSK tumbled on Thursday after a ruling by a US health agency narrowed usage recommendations for all respiratory syncytial virus (RSV) vaccines, restricting the addressable market for the company's Arexvy product.

LONDON MARKET OPEN: Nervy trade in London before US data

(Alliance News) - Stock prices in London opened lower on Thursday, despite peers in Europe climbing, with some of the FTSE 100 heavyweights in decline in early trade.

US CDC narrows age recommendation for RSV shots in US

June 26 (Reuters) - The U.S. CDC on Wednesday narrowed its recommendation for use of respiratory syncytial virus vaccines in older adults this year and held off on recommending their use for adults under age 60.

US advisers to consider RSV shots as GSK looks to keep market lead

June 26 (Reuters) - A committee of outside experts to the U.S. CDC are set to vote on whether to expand the age group of adults who should receive respiratory syncytial virus (RSV) vaccines this year, as GSK battles rival Pfizer and new entrant Moderna to keep its top position in the market.

Merck KGaA shares plunge after cancer drug hopeful fails

FRANKFURT, June 25 (Reuters) - Shares in Germany's Merck KGaA slumped 8.9% at the open on Tuesday after the diversified group late on Monday said a trial testing a head and neck cancer drug, previously seen as promising, would be stopped for lack of efficacy.

TOP NEWS: GSK hails Omjjara approval in Japan; Jemperli review in EU

(Alliance News) - GSK PLC on Monday said it has landed an approval in Japan and also highlighted regulatory progress in the EU.

LONDON BRIEFING: Prudential announces buyback; Frasers and THG in deal

(Alliance News) - London's FTSE 100 is called to open lower at the start of the week, with share price falls for major US tech shares, Nvidia included, spooking investors on this side of the Atlantic.

GSK reports regulatory progress for Omjjara, Jemperli

(Sharecast News) - GSK announced on Monday that it has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for 'Omjjara', or momelotinib, as a treatment for myelofibrosis.

Industry groups back drugmakers' appeal in Zantac cancer lawsuits

June 20 (Reuters) - A bid by GSK and other drugmakers to stop more than 70,000 lawsuits in Delaware over discontinued heartburn drug Zantac has received the backing of leading U.S. industry groups, including the United States Chamber of Commerce and Pharmaceutical Research and Manufacturers of America.